AHAshleigh van Heerden

Ashleigh van Heerden

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ashleigh van Heerden has a total of 41 co-authors. Here are the top co-authors by number of shared publications:

  • Lyn-Marie Birkholtz

    University of Pretoria Institute for Sustainable Malaria Control (UP ISMC), School of Health Systems and Public Health (SHSPH), University of Pretoria, South Africa

    3 shared publications
  • Andre Horatscheck

    Marc Nazare ‐ Chemical Biology Leibniz Institute fur Molecular Pharmacologie Robert‐Roessle‐Strasse 10 13125 Berlin Germany

    1 shared publication
  • Anjo Theron

    Future Production: Chemicals, Council for Scientific and Industrial Research Pretoria South Africa

    1 shared publication
  • Anne N. Cowell

    Division of Host-Microbe Systems & Therapeutics, Department of Pediatrics, University of California San Diego, La Jolla, CA, 92093-076, USA

    1 shared publication
  • Belinda Bezuidenhout

    Department of Molecular Medicine and Hematology, Wits Research Institute for Malaria, School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, 2193, South Africa

    1 shared publication
  • Bryan Greenhouse

    Department of Medicine, University of California, San Francisco, USA

    1 shared publication

Latest Publications

  • Open Access

    Machine learning approaches identify chemical features for stage-specific antimalarial compounds

    by Ashleigh van Heerden, Gemma Turon, Miquel Duran-Frigola, Nelishia Pillay, Lyn-Marié Birkholtz

    Efficacy data from diverse chemical libraries, screened against the various stages of the malaria parasite Plasmodium falciparum , including asexual blood stage (ABS) parasites and transmissible gametocytes, serves as a valuable reservoir of information on the chemical space of compounds that are either active (or not) against the parasite. We postulated that this data can be mined to define chemical features associated with sole ABS activity and/or those that provide additional life cycle activity profiles like gametocytocidal activity. Additionally, this information could provide chemical features associated with inactive compounds, which could eliminate any future unnecessary screening of similar chemical analogues. Therefore, we aimed to use machine learning to identify the chemical space associated with stage-specific antimalarial activity. We collected data from various chemical libraries that were screened against the asexual (126 374 compounds) and sexual (gametocyte) stages of the parasite (93 941 compounds), calculated the compounds’ molecular fingerprints and trained machine learning models to recognize stage-specific active and inactiv compounds. We were able to build several models that predicts compound activity against ABS and dual-activity against ABS and gametocytes, with Support Vector Machines (SVM) showing superior abilities with high recall (90% and 66%) and low false positive predictions (15% and 1%). This allowed identification of chemical features enriched in active and inactive populations, an important outcome that could be mined for essential chemical features to streamline hit-to-lead optimization strategies of antimalarial candidates. The predictive capabilities of the models held true in diverse chemical spaces, indicating that the ML models are therefore robust and can serve as a prioritization tool to drive and guide phenotypic screening and medicinal chemistry programs. For Table of Contents Graphic Only:

  • Open Access

    WITHDRAWN: Genetic complexity alters drug susceptibility of asexual and gametocyte stages of P. falciparum to antimalarial candidates

    by Nicola Greyling, Mariëtte van der Watt, Hazel Gwarinda, Ashleigh van Heerden, Bryan Greenhouse, Didier Leroy, Jandeli Niemand, Lyn-Marié Birkholtz

    Malaria elimination requires interventions able to target both the asexual blood stage (ABS) parasites and transmissible gametocyte stages of Plasmodium falciparum. Lead antimalarial candidates are evaluated against clinical isolates to address key concerns regarding efficacy and confirm that the current, circulating parasites from endemic regions lacks resistance against these candidates. Whilst this has largely been performed on ABS parasites, limited data is available on the transmission-blocking efficacy of compounds with multistage activity. Here, we evaluated the efficacy of lead antimalarial candidates against both ABS parasites and late-stage gametocytes side-by-side, against clinical P. falciparum isolates from southern Africa. We additionally correlated drug efficacy to the genetic diversity of the clinical isolates as determined with a panel of well-characterized, genome spanning microsatellite (MS) markers. Our data indicate varying sensitivities of the isolates to key antimalarial candidates, both for ABS parasites and gametocyte stages. While ABS parasites were efficiently killed, irrespective of genetic complexity, antimalarial candidates lost some gametocytocidal efficacy when the gametocytes originated from genetically complex, multiple clone infections. This suggests a fitness benefit to multiclone isolates to sustain transmission and reduce drug susceptibility. In conclusion, this is the first study to investigate the efficacy of antimalarial candidates on both ABS parasites and gametocytes from P. falciparum clinical isolates where the influence of parasite genetic complexity is highlighted, ultimately aiding the malaria elimination agenda.

  • Open Access

    Multistage and transmission-blocking targeted antimalarials discovered from the open-source MMV Pandemic Response Box

    by Janette Reader, Mariëtte E. van der Watt, Dale Taylor, Claire Le Manach, Nimisha Mittal, Sabine Ottilie, Anjo Theron, Phanankosi Moyo, Erica Erlank, Luisa Nardini, et al.

    Chemical matter is needed to target the divergent biology associated with the different life cycle stages of Plasmodium. Here, we report the parallel de novo screening of the Medicines for Malaria Venture (MMV) Pandemic Response Box against Plasmodium asexual and liver stage parasites, stage IV/V gametocytes, gametes, oocysts and as endectocides. Unique chemotypes were identified with both multistage activity or stage-specific activity, including structurally diverse gametocyte-targeted compounds with potent transmission-blocking activity, such as the JmjC inhibitor ML324 and the antitubercular clinical candidate SQ109. Mechanistic investigations prove that ML324 prevents histone demethylation, resulting in aberrant gene expression and death in gametocytes. Moreover, the selection of parasites resistant to SQ109 implicates the druggable V-type H+-ATPase for the reduced sensitivity. Our data therefore provides an expansive dataset of compounds that could be redirected for antimalarial development and also point towards proteins that can be targeted in multiple parasite life cycle stages.